A Study of Valemetostat Tosylate Plus Pembrolizumab Versus Pembrolizumab Alone in First-Line NSCLC Without Actionable Genomic Alterations
NCT ID: NCT06644768
Last Updated: 2025-10-09
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE1/PHASE2
137 participants
INTERVENTIONAL
2024-10-30
2030-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)
NCT02578680
A Study of Pembrolizumab (MK-3475) With or Without Maintenance Olaparib in First-line Metastatic Squamous Non-small Cell Lung Cancer (NSCLC, MK-7339-008/KEYLYNK-008)
NCT03976362
Study of Pembrolizumab (MK-3475) Versus Platinum-Based Chemotherapy for Participants With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Advanced or Metastatic Non-Small Cell Lung Cancer (MK-3475-042/KEYNOTE-042)
NCT02220894
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
NCT02142738
A Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung Cancer.
NCT05984277
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Phase 1b: Pembrolizumab + Valemetostat Tosylate
Participants will be provided with pembrolizumab at standard dose of 200 mg intravenously (IV) Q3W, and valemetostat will be provided per a dose escalation schedule, with an initial starting dose of 150 mg by mouth once daily.
valemetostat tosylate
Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
pembrolizumab
One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Phase 2: Pembrolizumab + Valemetostat Tosylate
Participants will be provided with pembrolizumab at standard dose of 200 mg IV Q3W, and valemetostat will be provided per recommended phase 2 dose (RP2D)
valemetostat tosylate
Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
pembrolizumab
One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Phase 2: Pembrolizumab
Participants will be provided with pembrolizumab at standard dose of 200 mg IV Q3W
pembrolizumab
One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
valemetostat tosylate
Valemetostat will be administered orally once daily until RP2D of valemetostat is determined.
pembrolizumab
One IV infusion Q3W on D1 of each 21-day cycle for a maximum of 35 cycles.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Is an adult ≥18 years of age or the minimum legal age (whichever is greater) at the time of informed consent. (Follow local regulatory requirements if the legal age of adult voluntary consent for trial participation is \>18 years old).
3. Has histologically documented NSCLC that meets all of the following criteria:
1. Has no prior systemic therapy for advanced or metastatic disease.
2. Has Stage IIIB or IIIC disease and is not a candidate for surgical resection or definitive chemoradiation, or Stage IV NSCLC disease at the time of enrollment/randomization (based on the American Joint Committee on Cancer, Eighth Edition). Participants with early-stage NSCLC who have relapsed should be restaged during Screening to ensure their eligibility for the trial.
3. Has documented negative test results for EGFR, ALK, and ROS1 actionable genomic alterations based on analysis of tumor tissue. If test results for EGFR, ALK, and ROS1 are not available, participants are required to undergo testing performed locally for these genomic alterations.
Participants with squamous NSCLC are only required to undergo EGFR, ALK, and ROS1 testing if they have no history of tobacco smoking or were diagnosed with NSCLC at \<40 years of age.
4. Has no known actionable genomic alterations in NTRK, BRAF, RET, MET, or other actionable oncogenic drivers with locally approved therapies (testing for genomic alterations besides EGFR, ALK, and ROS1 is not required prior to enrollment/randomization). Participants whose tumors harbor KRAS mutations are eligible for the trial.
4. Has measurable disease on CT or MRI based on local imaging assessment using RECIST v1.1
5. Has a tumor expressing PD-L1 TPS ≥50% as determined by local testing using 22C3 pharmDx PD-L1 IHC assay. In regions where PD-L1 (TPS ≥50%) testing by 22C3 pharmDx is not considered SOC, PD-L1 expression levels will be determined by central testing (minimum of 6 slides).
6. Has provided a formalin-fixed tumor tissue sample for the assessment of biomarkers. This tissue requirement is in addition to the tissue required for PD-L1 testing for tissue screening purposes. If a documented law or regulation prohibits (or does not approve) sample collection, then such sample will not be collected.
7. Has an ECOG PS of 0 or 1 at Screening.
Exclusion Criteria
1. Any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX40, or CD137).
2. Has previously been treated with any enhancer of zeste homolog inhibitors.
2. Participants who received adjuvant or neoadjuvant therapy other than those listed in the exclusion criterion above are eligible if the adjuvant/neoadjuvant therapy was completed at least 6 months prior to the current diagnosis of advanced or metastatic disease.
3. Has received a live vaccine or live attenuated vaccine within 30 days prior to the first dose of trial intervention. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette-Guérin, and typhoid vaccines. Note: Administration of killed vaccines is allowed.
4. Has an active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of systemic disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
Inhaled, intranasal, intraocular, intra-articular, or topical steroids and adrenal replacement steroids are permitted in the absence of active autoimmune disease.
5. Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (at doses exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial intervention. Note: Short-course systemic corticosteroids (eg, prevention of/treatment for transfusion reaction) or steroid use for a noncancer indication (eg, adrenal replacement) is permissible.
6. Has a known active or untreated CNS metastases and/or carcinomatous meningitis. Participants with previously treated brain metastases may participate, provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks by repeat imaging (note: repeat imaging should be performed during trial screening), clinically stable, and without requirement of steroid treatment for at least 14 days before the first dose of trial intervention. Note: A CT scan or MRI scan of the brain at Baseline is required for all participants. For participants in whom CNS metastases are first discovered at Screening, the treating investigator should delay trial intervention to complete any necessary treatment followed by a proper washout period and document the stability of CNS metastases with repeat imaging at least 4 weeks later (in which case repetition of all screening activities may be required).
7. Has uncontrolled or significant cardiovascular disease, including the following:
1. Mean QT interval corrected for heart rate using Fridericia's formula \>470 ms (based on the average of screening triplicate 12-lead ECG determinations)
2. Myocardial infarction within 6 months prior to Screening
3. Uncontrolled angina pectoris within 6 months prior to Screening
4. New York Heart Association Class 3 or 4 congestive heart failure
5. Uncontrolled hypertension (resting systolic blood pressure \>160 mmHg or diastolic blood pressure \>100 mmHg)
8. Has a history of (noninfectious) ILD/pneumonitis that required steroids, has current ILD/pneumonitis, or where suspected ILD/pneumonitis cannot be ruled out by imaging at Screening.
9. Has a history of radiation pneumonitis.
10. Has had an allogenic tissue/solid organ transplant.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Merck Sharp & Dohme LLC
INDUSTRY
Daiichi Sankyo
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of California San Diego (Ucsd)-Moores Cancer Center
La Jolla, California, United States
California Research Institute
Los Angeles, California, United States
Valkyrie Clinical Trials
Los Angeles, California, United States
Mayo Clinic Hospital
Jacksonville, Florida, United States
BRCR Global
Plantation, Florida, United States
University of Kentucky Medical Center
Lexington, Kentucky, United States
Pikeville Medical Center
Pikeville, Kentucky, United States
Mayo Clinic - Rochester
Rochester, Minnesota, United States
Columbia University Irving Medical Center
New York, New York, United States
Montefiore Medical Center
The Bronx, New York, United States
Thomas Jefferson University, Sidney Kimmel Cancer Center
Philadelphia, Pennsylvania, United States
Virginia Cancer Specialist
Fairfax, Virginia, United States
Hospital Italiano de Buenos Aires
Buenos Aires, , Argentina
Instituto Alexander Fleming
Buenos Aires, , Argentina
Sanatorio Allende
Córdoba, , Argentina
Fundacion Ars Medica
N Salvador de Jujuy, , Argentina
Centro de Investigacion Pergamino Sa
Pergamino, , Argentina
Instituto Medico de La Fundacion Estudios Clinicos
Rosario, , Argentina
Clinica Viedma S.A.
Viedma, , Argentina
Centro de Pesquisas Clinica Reichow
Blumenau, , Brazil
Clínica de Neoplasias Litoral Ltda.
ItajaĂ-, , Brazil
CINPAM Centro Integrado De Pesquisa Da Amazonia
Manaus, , Brazil
Liga Norte-Rio-Grandense Contra o Câncer
Natal, , Brazil
Hospital Nossa Senhora da Conceicao
Porto Alegre, , Brazil
Cepho - Centro de Estudos E Pesquisas de Hematologia E Oncologia
Santo André, , Brazil
Fundacao Faculdade Regional de Medicina de Sao Jose Do Rio Preto
Sao Jose Rio Preto, , Brazil
Jilin Cancer Hospital
Changchun, , China
The First Hospital of Jilin University
Changchun, , China
Chengdu Shang Jin Nan Fu Hospital
Chengdu, , China
Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
Hangzhou, , China
Harbin Medical University Cancer Hospital
Harbin, , China
Jiamusi Cancer Hospital
Jiamusi, , China
Shanghai East Hospital
Shanghai, , China
The First Hospital of China Medical University
Shenyang, , China
Tianjin Medical University Cancer Institute & Hospital
Tiyuan, , China
Henan Cancer Hospital
Zhengzhou, , China
Kyushu University Hospital
Fukuoka, , Japan
National Cancer Center Hospital East
Kashiwa, , Japan
Cancer Institute Hospital of JFCR
Kōtoku, , Japan
NHO Nagoya Medical Center
Nagoya, , Japan
Kitasato University Hospital
Sagamihara-shi, , Japan
Severance Hospital, Yonsei University Health System
Seoul, , South Korea
Samsung Medical Center
Seoul, , South Korea
Seoul National University Hospital
Seoul, , South Korea
The Catholic University of Korea, St. Vincent'S Hospital
Suwon, , South Korea
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MK-3475-F85
Identifier Type: OTHER
Identifier Source: secondary_id
KEYNOTE-F85
Identifier Type: OTHER
Identifier Source: secondary_id
DS3201-330
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.